- $7.48m
- $0.48m
- $1.49m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.124 | 0 | 0 | 0.262 | 1.49 |
Cost of Revenue | |||||
Gross Profit | — | — | — | 0.075 | 0.267 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 9.69 | 8.37 | 7.8 | 19.7 | 24.8 |
Operating Profit | -9.57 | -8.37 | -7.8 | -19.4 | -23.3 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -9.34 | -8.34 | -7.8 | -19.2 | -22.8 |
Net Income After Taxes | -9.34 | -8.34 | -7.8 | -19.2 | -22.8 |
Net Income Before Extraordinary Items | |||||
Net Income | -9.34 | -8.34 | -7.8 | -19.2 | -22.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -9.34 | -8.34 | -7.8 | -19.2 | -22.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -30.5 | -28.7 | -32.3 | -56 | -57 |
Dividends per Share |